NOP antagonists have attracted interest as potential therapeutic targets for the treatment of psychiatric and neurological disorders such as depression, Parkinson’s disease, obesity, schizophrenia-associated cognitive impairment, drug abuse and neuropathic pain. Here, PNOC is linked to obesity due to melanocortin 4 receptor deficiency.